requir
signific
impact
clinic
outcom
immunomodulatori
therapi
downregul
cytokin
storm
may
provid
insight
treatment
combin
use
immunomodulatori
agentto
reduc
cytokin
stormwith
antivir
agent
may
give
physician
time
provid
support
treatment
patient
corticosteroid
among
commonli
use
drug
immunomodulatori
therapi
infecti
diseas
howev
use
corticosteroid
treatment
caus
host
immun
suppress
delay
viral
clearanc
recent
studi
result
provid
inform
help
handl
dilemma
studi
xian
jiaotongliverpool
univers
found
use
corticosteroid
influenc
viral
clearanc
time
length
hospit
stay
durat
symptom
patient
mild
studi
includ
patient
found
treatment
methylprednisolon
decreas
risk
death
hazard
ratio
confid
interv
among
patient
acut
respiratori
distress
syndrom
ard
base
find
use
corticosteroid
consid
benefici
sever
case
especi
partient
ard
mild
case
accord
treatment
experi
china
cautiou
use
corticosteroid
recommend
certain
critic
ill
patient
eg
hypoxaemia
lowtomoder
dose
mgkgday
methylprednisolon
equival
short
durat
day
state
diagnosi
treatment
protocol
novel
coronaviru
pneumonia
trial
version
issu
nation
health
commiss
china
recent
chloroquin
deriv
hydroxychloroquin
use
treatment
februari
result
chines
patient
show
chloroquin
phosphat
good
efficaci
french
doctor
conduct
openlabel
nonrandom
clinic
trial
patient
receiv
hydroxychloroquin
treatment
show
good
efficaci
chloroquin
hydroxychloroquin
weak
base
abl
accumul
acid
organel
eg
lysosom
increas
endosomallysosom
ph
inhibit
viral
replic
addit
antimalari
antivir
effect
antiinflammatori
properti
demonstr
treatment
autoimmun
diseas
rheumatoid
arthriti
lupu
erythematosu
chloroquin
hydroxychloroquin
inhibit
major
histocompat
complex
class
ii
express
antigen
present
immun
activ
reduc
express
cell
via
tolllik
receptor
signal
cga
stimul
interferon
gene
thu
chloroquin
hydroxychloroquin
reduc
product
variou
proinflammatori
cytokin
tumour
necrosi
factor
involv
cytokin
storm
immunomodulatori
effect
synerg
antivir
effect
treatment
immunomodulatori
agent
directli
target
key
cytokin
involv
may
also
help
allevi
hyperinflamm
symptom
sever
case
elev
level
inflammatori
indic
blood
report
predict
fatal
outcom
patient
tocilizumab
specif
monoclon
antibodi
block
recommend
use
sever
critic
ill
patient
extens
lesion
bilater
lung
confirm
elev
level
diagnosi
treatment
protocol
novel
coronaviru
pneumonia
trial
version
issu
nation
health
commiss
china
retrospect
analysi
sever
case
show
treatment
tocilizumab
led
reduct
fever
lung
lesion
opac
recov
percentag
lymphocyt
peripher
blood
bind
transmembran
receptor
solubl
receptor
result
complex
combin
signal
transduc
compon
activ
inflammatori
respons
tocilizumab
bind
specif
block
signal
transduct
tocilizumab
good
therapeut
option
cytokin
releas
syndrom
chimer
antigen
receptor
tcell
immunotherapi
howev
clinic
experi
tocilizumab
viral
diseas
limit
retrospect
studi
patient
juvenil
idiopath
arthriti
infect
influenza
reduc
fever
reduc
level
creactiv
protein
observ
patient
receiv
tocilizumab
compar
patient
receiv
tocilizumab
meanwhil
inhibit
tocilizumab
exacerb
increas
suscept
influenza
viru
infect
howev
well
document
warn
increas
risk
opportunist
infect
includ
tuberculosi
fungal
viral
infect
caus
monoclon
antibodi
treatment
rheumatoid
arthriti
high
cost
safeti
risk
may
barrier
wide
use
tocilizumab
treatment
earli
march
chines
clinician
investig
use
immunomodulatori
agent
ulinastatin
treatment
cytokin
storm
ulinastatin
serin
proteas
inhibitor
antiinflammatori
properti
includ
inhibit
use
treatment
acut
pancreat
sepsi
japan
china
expert
consensu
shanghai
ulinastatin
recommend
patient
exacerb
lung
lesion
overal
certain
immunomodulatori
agent
good
safeti
profil
may
consid
use
combin
antivir
drug
treatment
sever
critic
case
compet
interest
none
declar
ethic
approv
requir
articl
edit
extensivelypleas
check
proof
care
ensur
mean
alter
